|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CEACAM6 |
Gene summary for CEACAM6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CEACAM6 | Gene ID | 4680 |
| Gene name | CEA cell adhesion molecule 6 | |
| Gene Alias | CD66c | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0001952 | UniProtAcc | P40199 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4680 | CEACAM6 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.49e-05 | -3.34e-01 | 0.0155 |
| 4680 | CEACAM6 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.28e-04 | -2.93e-01 | 0.0674 |
| 4680 | CEACAM6 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.57e-06 | -2.91e-01 | 0.294 |
| 4680 | CEACAM6 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.13e-08 | 1.23e+00 | 0.281 |
| 4680 | CEACAM6 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.74e-08 | 7.54e-01 | 0.3859 |
| 4680 | CEACAM6 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.49e-17 | 1.55e+00 | 0.2585 |
| 4680 | CEACAM6 | A015-C-203 | Human | Colorectum | FAP | 1.28e-07 | -2.82e-01 | -0.1294 |
| 4680 | CEACAM6 | A001-C-119 | Human | Colorectum | FAP | 1.07e-02 | -3.19e-01 | -0.1557 |
| 4680 | CEACAM6 | A002-C-205 | Human | Colorectum | FAP | 9.77e-06 | -3.17e-01 | -0.1236 |
| 4680 | CEACAM6 | A014-C-108 | Human | Colorectum | FAP | 1.31e-03 | -3.28e-01 | -0.124 |
| 4680 | CEACAM6 | A001-C-104 | Human | Colorectum | FAP | 3.29e-04 | -2.69e-01 | 0.0184 |
| 4680 | CEACAM6 | A015-C-006 | Human | Colorectum | FAP | 2.14e-03 | -3.22e-01 | -0.0994 |
| 4680 | CEACAM6 | A015-C-106 | Human | Colorectum | FAP | 3.28e-04 | -2.59e-01 | -0.0511 |
| 4680 | CEACAM6 | A002-C-114 | Human | Colorectum | FAP | 7.47e-03 | -2.71e-01 | -0.1561 |
| 4680 | CEACAM6 | A015-C-104 | Human | Colorectum | FAP | 6.27e-09 | -3.09e-01 | -0.1899 |
| 4680 | CEACAM6 | A015-C-202 | Human | Colorectum | FAP | 2.33e-09 | -3.45e-01 | -0.0849 |
| 4680 | CEACAM6 | A001-C-014 | Human | Colorectum | FAP | 1.06e-04 | -2.22e-01 | 0.0135 |
| 4680 | CEACAM6 | A002-C-016 | Human | Colorectum | FAP | 4.35e-02 | -9.82e-02 | 0.0521 |
| 4680 | CEACAM6 | A001-C-203 | Human | Colorectum | FAP | 2.42e-07 | -3.17e-01 | -0.0481 |
| 4680 | CEACAM6 | A002-C-116 | Human | Colorectum | FAP | 2.63e-06 | -2.42e-01 | -0.0452 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000195418 | Esophagus | ESCC | positive regulation of cell-matrix adhesion | 40/8552 | 58/18723 | 2.83e-04 | 1.71e-03 | 40 |
| GO:002240720 | Esophagus | ESCC | regulation of cell-cell adhesion | 239/8552 | 448/18723 | 5.88e-04 | 3.19e-03 | 239 |
| GO:002240919 | Esophagus | ESCC | positive regulation of cell-cell adhesion | 155/8552 | 284/18723 | 1.50e-03 | 7.06e-03 | 155 |
| GO:20008113 | Esophagus | ESCC | negative regulation of anoikis | 14/8552 | 17/18723 | 2.22e-03 | 9.78e-03 | 14 |
| GO:00341143 | Esophagus | ESCC | regulation of heterotypic cell-cell adhesion | 18/8552 | 26/18723 | 1.32e-02 | 4.31e-02 | 18 |
| GO:00341135 | Esophagus | ESCC | heterotypic cell-cell adhesion | 37/8552 | 61/18723 | 1.32e-02 | 4.31e-02 | 37 |
| GO:00071607 | Lung | IAC | cell-matrix adhesion | 63/2061 | 233/18723 | 7.08e-12 | 4.27e-09 | 63 |
| GO:00315897 | Lung | IAC | cell-substrate adhesion | 85/2061 | 363/18723 | 8.57e-12 | 4.27e-09 | 85 |
| GO:00019527 | Lung | IAC | regulation of cell-matrix adhesion | 40/2061 | 128/18723 | 4.69e-10 | 9.93e-08 | 40 |
| GO:00108108 | Lung | IAC | regulation of cell-substrate adhesion | 57/2061 | 221/18723 | 5.09e-10 | 1.04e-07 | 57 |
| GO:00457858 | Lung | IAC | positive regulation of cell adhesion | 87/2061 | 437/18723 | 2.59e-08 | 3.13e-06 | 87 |
| GO:00108118 | Lung | IAC | positive regulation of cell-substrate adhesion | 29/2061 | 123/18723 | 5.35e-05 | 1.21e-03 | 29 |
| GO:00224078 | Lung | IAC | regulation of cell-cell adhesion | 76/2061 | 448/18723 | 8.16e-05 | 1.68e-03 | 76 |
| GO:00019546 | Lung | IAC | positive regulation of cell-matrix adhesion | 16/2061 | 58/18723 | 3.85e-04 | 5.87e-03 | 16 |
| GO:00224097 | Lung | IAC | positive regulation of cell-cell adhesion | 49/2061 | 284/18723 | 9.60e-04 | 1.16e-02 | 49 |
| GO:000716012 | Lung | AIS | cell-matrix adhesion | 60/1849 | 233/18723 | 2.19e-12 | 2.55e-09 | 60 |
| GO:003158913 | Lung | AIS | cell-substrate adhesion | 80/1849 | 363/18723 | 3.80e-12 | 3.16e-09 | 80 |
| GO:001081013 | Lung | AIS | regulation of cell-substrate adhesion | 55/1849 | 221/18723 | 7.48e-11 | 2.49e-08 | 55 |
| GO:000195212 | Lung | AIS | regulation of cell-matrix adhesion | 38/1849 | 128/18723 | 2.93e-10 | 7.42e-08 | 38 |
| GO:004578513 | Lung | AIS | positive regulation of cell adhesion | 77/1849 | 437/18723 | 3.40e-07 | 2.83e-05 | 77 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CEACAM6 | SNV | Missense_Mutation | rs782366279 | c.557N>T | p.Pro186Leu | p.P186L | P40199 | protein_coding | tolerated(0.1) | benign(0.077) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| CEACAM6 | insertion | Frame_Shift_Ins | novel | c.651_652insT | p.Gln218SerfsTer10 | p.Q218Sfs*10 | P40199 | protein_coding | TCGA-A8-A07F-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CEACAM6 | insertion | Nonsense_Mutation | novel | c.652_653insGTGCATCTGTTGTGTGACACACACACCTGCCAGGGGCTTTTA | p.Gln218delinsArgAlaSerValValTerHisThrHisLeuProGlyAlaPheLys | p.Q218delinsRASVV*HTHLPGAFK | P40199 | protein_coding | TCGA-A8-A07F-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CEACAM6 | insertion | Nonsense_Mutation | novel | c.706_707insCACACAGAAAATACAGCTAGGGGGGCAAAGTAGGACTAAAGCTT | p.Gly236AlafsTer7 | p.G236Afs*7 | P40199 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| CEACAM6 | SNV | Missense_Mutation | rs143238640 | c.994N>A | p.Gly332Ser | p.G332S | P40199 | protein_coding | tolerated(0.75) | benign(0.08) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CEACAM6 | SNV | Missense_Mutation | c.29G>A | p.Arg10Lys | p.R10K | P40199 | protein_coding | tolerated(0.36) | benign(0.331) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CEACAM6 | SNV | Missense_Mutation | novel | c.215N>C | p.Arg72Thr | p.R72T | P40199 | protein_coding | tolerated(0.68) | benign(0.012) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CEACAM6 | SNV | Missense_Mutation | c.808N>A | p.Ser270Thr | p.S270T | P40199 | protein_coding | tolerated(0.11) | probably_damaging(0.936) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CEACAM6 | insertion | Frame_Shift_Ins | novel | c.650_651insG | p.Ile217MetfsTer11 | p.I217Mfs*11 | P40199 | protein_coding | TCGA-AA-3856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| CEACAM6 | insertion | Frame_Shift_Ins | novel | c.650_651insG | p.Ile217MetfsTer11 | p.I217Mfs*11 | P40199 | protein_coding | TCGA-AA-3952-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4680 | CEACAM6 | CELL SURFACE, DRUGGABLE GENOME | ANTISERUM | 6388310 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |